Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events

Ryuji Yasumatsu, Mioko Matsuo, Takahiro Wakasaki, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Rina Jiromaru, Ryutaro Uchi, Kazuki Hashimoto, Takashi Nakagawa

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Significant immune-related adverse events (irAEs) requiring therapy discontinuation sometimes occur. The influence of discontinuation on disease control after an irAE is unclear. Objectives: The aim of this study was to investigate whether or not patients continued to show a response or durable disease control even after stopping therapy following an irAE. Material and Methods: The response after nivolumab monotherapy discontinuation was examined for 14 patients in whom therapy was stopped without progression. Results: The best response was CR in 5 (36%) patients, PR in 8 (57%) patients and SD in 1 (7%) patient. The estimated 1-year overall and progression-free survival rates were 92.9% and 78.6%, respectively. The best response during nivolumab therapy in patients who developed PD was CR in 0 of 5 patients (0%), PR in 3 of 8 patients (38%) and SD in 1 patient (100%). Patients obtaining CR tended to have a lower risk of PD than those with PR or SD. Conclusions and Significance: Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.

Original languageEnglish
JournalActa Oto-Laryngologica
DOIs
Publication statusAccepted/In press - 2020

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events'. Together they form a unique fingerprint.

Cite this